Merck & Co (MRK)
80.02
-0.77 (-0.95%)
NYSE · Last Trade: Aug 6th, 1:29 PM EDT
Detailed Quote
Previous Close | 80.79 |
---|---|
Open | 80.29 |
Bid | 80.01 |
Ask | 80.03 |
Day's Range | 79.80 - 81.32 |
52 Week Range | 73.31 - 120.30 |
Volume | 5,586,354 |
Market Cap | 202.56B |
PE Ratio (TTM) | 11.65 |
EPS (TTM) | 6.9 |
Dividend & Yield | 3.240 (4.05%) |
1 Month Average Volume | 12,982,562 |
Chart
About Merck & Co (MRK)
Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
News & Press Releases
Merck & Co. (MRK) is a top dividend stock with a 4.06% yield, strong profitability, and solid financials, making it a reliable choice for income investors.
Via Chartmill · August 6, 2025
Their steep payouts make them worth a look, but a big dividend doesn't inherently make a stock worth owning.
Via The Motley Fool · August 6, 2025
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
NetworkNewsWire Editorial Coverage : As America’s population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration’s “Make America Healthy Again” initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) ( Profile ) is making strides with its HyBryte(“TM”) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (“CTCL”), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte’s active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space, including Pfizer Inc. (NYSE: PFE), Merck & Co Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY) and…
Via Investor Brand Network · August 4, 2025
Via FinancialNewsMedia · August 4, 2025
This weight loss drugmaker may be significantly undervalued right now.
Via The Motley Fool · August 4, 2025
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the pharmaceutical giant and the wider healthcare industry, which has been navigating a complex landscape of regulatory scrutiny, patent expirations,
Via MarketMinute · August 4, 2025
If you are looking for dividend stocks, a good place to start is with unloved stocks like these, with yields of up to 6.4%.
Via The Motley Fool · August 2, 2025
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.
Via Benzinga · August 1, 2025
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinchstocktwits.com
Via Stocktwits · July 31, 2025
These stocks have all surged more than 1,000% since August 2020.
Via The Motley Fool · July 31, 2025
Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove investor interest.
Via Benzinga · July 30, 2025
A change in full-year guidance by management wasn't particularly welcome.
Via The Motley Fool · July 29, 2025
Shares of global pharmaceutical company Merck (NYSE:MRK)
fell 3.2% in the afternoon session after the company reported second-quarter financial results that missed revenue expectations and revealed a new multi-year cost-cutting initiative. The pharmaceutical giant posted total sales of $15.8 billion, representing a 2% decrease from the same period last year. This revenue shortfall was primarily driven by a steep 55% drop in sales for its Gardasil vaccine, which faced declining demand in China. While the company's earnings per share beat analysts' forecasts, investors appeared to focus on the top-line miss. Alongside the earnings, Merck announced a major restructuring plan aimed at saving $3 billion annually through measures that included layoffs and real estate reductions. The company stated these savings would be reinvested to support new product launches and its research pipeline.
Via StockStory · July 29, 2025
Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.
Via Benzinga · July 29, 2025
Merck posted lower Q2 earnings as vaccine sales dropped, but oncology and animal health segments saw strong growth; 2025 guidance slightly raised.
Via Benzinga · July 29, 2025
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Tuesday and stay ahead of the market trends.
Via Chartmill · July 29, 2025
The $3 billion will be reinvested to support new product launches and its pipeline across multiple therapeutic areas, Merck said.
Via Stocktwits · July 29, 2025
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Via Chartmill · July 29, 2025
Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $64.8 billion at the midpoint. Its non-GAAP profit of $2.13 per share was 5% above analysts’ consensus estimates.
Via StockStory · July 29, 2025
Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2025.
By Merck & Co., Inc. · Via Business Wire · July 29, 2025
If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%.
Via The Motley Fool · July 28, 2025